within Pharmacolibrary.Drugs.ATC.C;

model C04AC01_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1.0,
    Cl             = 0.0026666666666666666,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.00057,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Nicotinic acid (also known as niacin or vitamin B3) is a water-soluble vitamin used as a lipid-modifying agent for the treatment of dyslipidemia, especially to increase HDL cholesterol and lower triglycerides and LDL cholesterol. While it has been historically used for cardiovascular risk reduction, its use has declined due to side effects and the advent of more effective therapies. It is still approved in some countries as an adjunct in lipid disorders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported after intravenous administration in healthy adults.</p><h4>References</h4><ol><li><p>Liu, L, et al., &amp; Rabinowitz, JD (2018). Quantitative Analysis of NAD Synthesis-Breakdown Fluxes. <i>Cell metabolism</i> 27(5) 1067–1080.e5. DOI:<a href=&quot;https://doi.org/10.1016/j.cmet.2018.03.018&quot;>10.1016/j.cmet.2018.03.018</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29685734/&quot;>https://pubmed.ncbi.nlm.nih.gov/29685734</a></p></li><li><p>Trapani, G, et al., &amp; Biggio, G (2000). Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery. <i>Current medicinal chemistry</i> 7(2) 249–271. DOI:<a href=&quot;https://doi.org/10.2174/0929867003375335&quot;>10.2174/0929867003375335</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10637364/&quot;>https://pubmed.ncbi.nlm.nih.gov/10637364</a></p></li><li><p>Ding, RW, et al., &amp; Benet, LZ (1989). Pharmacokinetics of nicotinic acid-salicylic acid interaction. <i>Clinical pharmacology and therapeutics</i> 46(6) 642–647. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1989.200&quot;>10.1038/clpt.1989.200</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2598568/&quot;>https://pubmed.ncbi.nlm.nih.gov/2598568</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C04AC01_1;
